- S Tyagi, K Bhol, K Natarajan
- J Dermatol Sci
1 Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013; 14:11–18. 2 Lacouture M, Duvic M, Hauschild A et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18:314–22. 3 Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous cell carcinoma in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207–15. 4 Anforth R, Tembe V, Blumetti T et al. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res 2012; 25:569–72. 5 Ganzenmueller T, Hage E, Yakushko Y et al. No human virus sequences detected by next generation sequencing in benign verrucous skin tumors occurring in BRAF inhibitor treated patients. Exp Dermatol 2013; 22:725–9. 6 Ko CJ, McNiff JM, Iftner A et al. Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae. J Am Acad Dermatol 2013; 69: e95–6. 7 IARC. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007: 901–36. 8 Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4:8. 9 Antonsson A, Forslund O, Ekberg H et al. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 2000; 74:11636–41. 10 Falchook GS, Rady P, Hymes S et al. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol 2013; 149:322–6.